XBiotech Inc
Uždarymo kaina
2.31
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
2.26
Max
2.34
Pajamos | 21M -5.5M |
|---|---|
Pelnas, tenkantis vienai akcijai | -0.181 |
Darbuotojai | 87 |
EBITDA | 24M -5.1M |
Kitas uždarbis | 2026-08-11 |
|---|
Rinkos kapitalizacija | -4.9M 70M |
|---|---|
Ankstesnė atidarymo kaina | 2.31 |
Ankstesnė uždarymo kaina | 2.31 |
XBiotech Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.